Venus Remedies is currently trading at Rs. 257.80, up by 7.95 points or 3.18% from its previous closing of Rs. 249.85 on the BSE.
The scrip opened at Rs. 252.00 and has touched a high and low of Rs. 260.05 and Rs. 250.75 respectively. So far 18159 shares were traded on the counter.
The BSE group 'B ' stock of face value Rs. 10 has touched a 52 week high of Rs. 350.00 on 28-Apr-2014 and a 52 week low of Rs. 162.30 on 20-Aug-2013.
Last one week high and low of the scrip stood at Rs. 270.40 and Rs. 241.25 respectively. The current market cap of the company is Rs. 292.80 crore.
The promoters holding in the company stood at 37.51% while Institutions and Non-Institutions held 8.69% and 53.80% respectively.
Venus Remedies has received its first marketing authorization in Switzerland from Swiss drug authority – Swissmedic -- for Gemcitabine 200mg & 1g Injection through Venus Pharma GmbH. This market approval of critically important oncology drug Gemcitabine Injection will help Venus to strengthen its oncology portfolio.
The company is planning to launch this product in early next quarter within this fiscal year to expand its presence in the oncology space. Venus Pharma GmbH the German subsidiary will carry out complete analysis of the goods. The product will be launched in Switzerland market by Swiss Pharma GmbH with whom Venus has a marketing tie up.
Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: